Table 2.
Outcomes by Demographic, Clinical, and Treatment Characteristics of SECURE-IBD cohort
| Characteristica,b | Total N | Outpatient only, n (%) | Hospitalized, n (%) | ICU, n (%) | Ventilator, n (%) | Death, n (%) | ICU/Ventilator/death, n (%) |
|---|---|---|---|---|---|---|---|
| Overall | 525 | 363 (69) | 161 (31) | 24 (5) | 21 (4) | 16 (3) | 37 (7) |
| Age, y | |||||||
| 0–9 | 3 | 3 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 10–19 | 26 | 23 (88) | 3 (12) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 20–29 | 116 | 93 (80) | 23 (20) | 2 (2) | 1 (1) | 0 (0) | 2 (2) |
| 30–39 | 108 | 87 (81) | 20 (19) | 4 (4) | 2 (2) | 1 (1) | 4 (4) |
| 40–49 | 95 | 64 (67) | 31 (33) | 4 (4) | 3 (3) | 2 (2) | 5 (5) |
| 50–59 | 74 | 45 (61) | 29 (39) | 3 (4) | 5 (7) | 2 (3) | 6 (8) |
| 60–69 | 54 | 30 (56) | 24 (44) | 10 (19) | 9 (17) | 3 (6) | 11 (20) |
| 70–79 | 24 | 7 (29) | 17 (71) | 1 (4) | 1 (4) | 2 (8) | 3 (13) |
| >=80 | 23 | 9 (39) | 14 (61) | 0 (0) | 0 (0) | 6 (26) | 6 (26) |
| Sex | |||||||
| Male | 276 | 183 (66) | 93 (34) | 12 (4) | 9 (3) | 11 (4) | 21 (8) |
| Female | 243 | 175 (72) | 67 (28) | 12 (5) | 12 (5) | 5 (2) | 16 (7) |
| Disease type | |||||||
| CD | 312 | 228 (73) | 83 (27) | 12 (4) | 9 (3) | 5 (2) | 16 (5) |
| UC/unspecified | 210 | 133 (63) | 77 (37) | 12 (6) | 12 (6) | 11 (5) | 21 (10) |
| IBD disease activityc | |||||||
| Remission | 309 | 232 (75) | 76 (25) | 12 (4) | 14 (5) | 8 (3) | 19 (6) |
| Mild | 100 | 70 (70) | 30 (30) | 2 (2) | 1 (1) | 4 (4) | 5 (5) |
| Moderate/Severe | 100 | 52 (52) | 48 (48) | 9 (9) | 5 (5) | 3 (3) | 12 (12) |
| Unknown | 16 | 9 (56) | 7 (44) | 1 (6) | 1 (6) | 1 (6) | 1 (6) |
| Smoking | |||||||
| Current smoker | 23 | 12 (52) | 11 (48) | 0 (0) | 0 (0) | 1 (4) | 1 (4) |
| Non-smoker | 502 | 351 (70) | 150 (30) | 24 (5) | 21 (4) | 15 (3) | 36 (7) |
| Comorbidities | |||||||
| 0 | 351 | 272 (77) | 79 (23) | 11 (3) | 8 (2) | 4 (1) | 13 (4) |
| 1 | 110 | 74 (67) | 35 (32) | 4 (4) | 4 (4) | 4 (4) | 8 (7) |
| 2 | 35 | 10 (29) | 25 (71) | 4 (11) | 5 (14) | 3 (9) | 7 (20) |
| 3+ | 29 | 7 (24) | 22 (76) | 5 (17) | 4 (14) | 5 (17) | 9 (31) |
| IBD medicationd | |||||||
| Sulfasalazine/mesalamine | 117 | 60 (51) | 57 (49) | 12 (10) | 12 (10) | 9 (8) | 20 (17) |
| Budesonide | 18 | 9 (50) | 9 (50) | 3 (17) | 3 (17) | 1 (6) | 3 (17) |
| Oral/parenteral steroids | 37 | 11 (30) | 26 (70) | 6 (16) | 5 (14) | 4 (11) | 9 (24) |
| 6MP/azathioprine monotherapye | 53 | 29 (55) | 24 (45) | 3 (6) | 3 (6) | 1 (2) | 3 (6) |
| Methotrexate monotherapye | 5 | 2 (40) | 3 (60) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Anti-TNF without 6MP/AZA/MTX | 176 | 150 (85) | 25 (14) | 3 (2) | 1 (1) | 1 (1) | 4 (2) |
| Anti-TNF + 6MP/AZA/MTX | 52 | 32 (62) | 20 (38) | 4 (8) | 2 (4) | 2 (4) | 5 (10) |
| Anti-integrin | 50 | 34 (68) | 16 (32) | 2 (4) | 3 (6) | 0 (0) | 3 (6) |
| IL-12/23 inhibitor | 55 | 51 (93) | 4 (7) | 1 (2) | 0 (0) | 0 (0) | 1 (2) |
| JAK inhibitor | 8 | 7 (88) | 1 (13) | 1 (13) | 1 (13) | 1 (13) | 1 (13) |
| Other IBD medication | 22 | 13 (59) | 9 (41) | 1 (5) | 1 (5) | 0 (0) | 1 (5) |
AZA, azathioprine; IL, interleukin; MTX, methotrexate; 6MP, 6-mercaptopurine.
Unless otherwise specified, percentages do not include missing values or “unknown.” For all characteristics, less than 4% of data was missing and unknown, respectively, for each category.
Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.
By physician global assessment (PGA) at time of COVID-19 infection
At time of COVID-19 infection. Medication categories are not mutually exclusive unless otherwise noted.
Monotherapy indicates no concomitant TNF antagonist, anti-integrin, anti-IL12/23, or JAK inhibitor